PureTech Health plc

Regulatory Filings • May 9, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5318E

PureTech Health PLC

09 May 2017

PureTech Health Annual Capital Markets Meeting, London

Annual Capital Markets Meeting

PureTech Health plc ("PureTech Health" or the "Company", LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, is today holding its second annual Capital Markets Meeting in London. The Company will provide insight into its near-term commercialisation and monetisation strategy as well as insights into its growing research and development pipeline.

The meeting will take place in London from 13.00-17.00 BST and will feature PureTech Health presenters including members of the Company's Board of Directors and key scientific advisors. 

Speaker	Topic
Chris Viehbacher Independent Non-Executive Director, PureTech Health; Managing Partner at Gurnet Point Capital and Former CEO of Sanofi	Welcome: Perspectives on PureTech Health's unique place in biopharma ecosystem
Daphne Zohar Co-Founder & Chief Executive Officer, PureTech Health	Building a modern biopharma company
Near-Term Catalysts
LeRoux Jooste Chief Commercial Officer, Akili Interactive; Former CCO/SVP of Business Development at Ocata (Astellas)	Akili Interactive: Imagine what medicine can be
Eddie Martucci, Ph.D. Vice President, PureTech Health; Co-Founder and Chief Executive Officer, Akili Interactive
Raju Kucherlapati, Ph.D. Independent Non-Executive Director and Scientific Advisory Board Member, PureTech Health; Co-founder of Millennium Pharmaceuticals and Abgenix	Transitioning from a clinical to commercial-stage biopharma company
Eric Elenko, Ph.D. Chief of Research and Strategy, PureTech Health	Gelesis: Targeting the genesis of chronic disease
Follica: Resetting the clock on skin biology
John LaMattina, Ph.D. Independent Non-Executive Director, PureTech Health; Former President of Global Research and Development at Pfizer	Developing new classes of medicine
Bernat Olle, Ph.D. Vice President, PureTech Health; Co-Founder and Chief Executive Officer, Vedanta Biosciences	Vedanta Biosciences: Microbiome-derived immunotherapies
Partnering with Big Pharma to Advance Important New Medicines
Bennett Shapiro, M.D. Co-Founder & Non-Executive Director, PureTech Health; Former Executive Vice President of Research at Merck	Partnering with big pharma to advance important new medicines
Andrew Miller, Ph.D. Vice President, PureTech Health; Co-Founder and Chief Executive Officer, Karuna Pharmaceuticals	Karuna Pharmaceuticals: Treating cognition and psychosis associated with neurological disease
Chen Schor Senior Executive, PureTech Health; Co-Founder and Chief Executive Officer, resTORbio	resTORbio: Aging and the immune system
A Growing Immunology Pipeline and the Next Wave of Innovation
Joe Bolen, Ph.D. Chief Scientific Officer, PureTech Health; Former President and CSO of Moderna and former CSO of Millennium (Takeda)	The adaptive human systems and a growing immunology pipeline
Aleks Radovic-Moreno, Ph.D. Senior Associate, PureTech Health; Co-Founder of Commense, Alivio, and Vor; Formerly MIT	Commense: Developing microbiome-derived interventions for maternal and paediatric health Alivio: Treating chronic and acute inflammatory disorders Vor: Developing next-generation engineered cell therapies in oncology
Aleks Filipovic, M.D., Ph.D. Therapeutic Lead for Oncology, PureTech Health; Co-Founder of Nybo; Formerly Imperial College	Nybo: Developing monoclonal antibodies to target pancreatic cancer and other solid tumours
Grace Teo, Ph.D. Associate, PureTech Health; Co-Founder of Nybo; Formerly MIT	Concept stage programmes: The next wave of innovation
David Steinberg Chief Innovation Officer, PureTech Health	Translating innovation into medicine
Atul Pande, M.D. Chief Medical Officer, PureTech Health; Former Senior Vice President and Head of Neuroscience at GSK
Bharatt Chowrira, Ph.D., J.D. President and Chief of Business and Strategy, PureTech Health; Former President of Synlogic and COO of Auspex (Teva)	Unlocking value
Marjorie Scardino Senior Independent Director, PureTech Health; Former CEO of Pearson plc and The Economist	Closing remarks

If you would like to attend the event, please contact  PureTech.Event@fticonsulting.com 

About PureTech Health

PureTech Health (PureTech Health plc, PRTC.L) is an advanced, clinical-stage biopharmaceutical company developing novel medicines that modulate the adaptive human systems. PureTech's therapies target the dysfunctions in the immune, nervous, and gastro-intestinal systems by addressing the underlying pathophysiology of disease from a systems perspective rather than through a single receptor or pathway. The Company is advancing a rich pipeline that includes multiple human proof-of-concept studies and pivotal or registration studies expected to read out over the next 12-18 months. PureTech Health's growing research and development pipeline has been developed in collaboration with some of the world's leading scientific experts, who along with PureTech's experienced team and a stellar Board identify, analyse and advance very selectively the opportunities the Company believes hold the most promise for patients. This experienced and engaged team places PureTech Health at the forefront of ground-breaking science and technological innovation and leads the Company between and beyond existing disciplines. For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:

	PureTech Health	FTI Consulting
	Allison Mead +1 617 651 3156 amead@puretechhealth.com	Ben Atwell, Matthew Cole, Rob Winder +44 (0) 20 3727 1000

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAEAASPEFFXEAF